I-Mab has released a corporate presentation highlighting its advancements in cancer therapeutics, particularly focusing on givastomig, a novel bispecific antibody targeting CLDN18.2, which is being developed for gastric cancer treatment. The presentation outlines clinical data showcasing anti-tumor activity with limited toxicities and higher binding affinity across various CLDN18.2 expression levels. Gastric cancer, a global market valued at $12 billion, presents a significant opportunity for expansion into other tumor types. The company is progressing with a Phase 1b escalation study of givastomig in combination with nivolumab and chemotherapy, with topline data to be presented at the upcoming ESMO GI 2025. Additionally, I-Mab maintains a strong capital position with $168.6 million in cash, ensuring financial stability through major clinical readouts. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.